First Citizens Bank & Trust Co. Grows Stock Position in Dynavax Technologies Corporation $DVAX

First Citizens Bank & Trust Co. raised its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 191.5% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 43,633 shares of the biopharmaceutical company’s stock after buying an additional 28,666 shares during the period. First Citizens Bank & Trust Co.’s holdings in Dynavax Technologies were worth $433,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies in the 1st quarter valued at about $30,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,304 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Callan Family Office LLC purchased a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $107,000. Finally, Moloney Securities Asset Management LLC purchased a new position in shares of Dynavax Technologies in the 1st quarter valued at about $131,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

NASDAQ:DVAX opened at $10.38 on Monday. Dynavax Technologies Corporation has a 52 week low of $9.20 and a 52 week high of $14.63. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $1.22 billion, a P/E ratio of -22.57 and a beta of 1.13. The stock’s fifty day moving average is $10.02 and its two-hundred day moving average is $10.32.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $95.44 million for the quarter, compared to analysts’ expectations of $87.55 million. Equities analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Friday. Finally, Wall Street Zen upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dynavax Technologies presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Insider Activity

In other news, Director Scott Dunseth Myers acquired 3,800 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the completion of the acquisition, the director owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.98% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.